BioNTech BNT327-05, also called ROSETTA Breast-01, is a recruiting Phase 3 study for certain adults with locally recurrent, inoperable, or metastatic triple-negative breast cancer. Patients and caregivers researching triple‑negative breast cancer clinical trials may wish to ask an oncology team whether this study fits the person’s diagnosis, treatment history, PD-L1 test result, and overall health.
The trial evaluates pumitamig, also known as BNT327, PM8002, or BMS-986545, when given with chemotherapy. Pumitamig is investigational, meaning it has not been approved as a routine treatment for triple-negative breast cancer. Enrollment does not guarantee a personal medical benefit, and a research site must confirm eligibility before a patient can join.
Why This Trial May Be Relevant for Triple-Negative Breast Cancer
Triple-negative breast cancer, often shortened to TNBC, does not have estrogen receptors, progesterone receptors, or HER2 overexpression that can be targeted by some treatments used for other breast cancer types. The treatment options for triple-negative breast cancer can depend on whether the disease is early-stage, locally recurrent, or metastatic, as well as factors such as biomarker testing and prior therapy.
BNT327-05 is intended for people whose cancer has returned locally but cannot be removed surgically, or has spread to other parts of the body. It specifically focuses on people with PD-L1-negative disease who are considered ineligible for certain PD-1 or PD-L1 immunotherapy combinations based on their tumor testing. This makes the study particularly relevant to a triple-negative breast cancer clinical trials request involving limited first-line options.
How BioNTech BNT327-05 Is Designed
Pumitamig is a bispecific antibody designed to target PD-L1 and VEGF. In straightforward terms, the study is evaluating whether adding this investigational medicine to chemotherapy may affect outcomes compared with chemotherapy alone.
Participants are assigned by chance to one of two treatment groups:
- Investigational group: Pumitamig plus chemotherapy delivered by intravenous infusion.
- Comparison group: A matching placebo plus chemotherapy.
The study is randomized and double-blind. Randomized means assignment is based on chance rather than patient or clinician preference. Double-blind means that, during the blinded part of the study, participants and study personnel do not know which study treatment was assigned. A placebo is made to resemble the study drug but does not contain the active investigational medicine.
The trial plans to enroll approximately 558 participants. The publicly available study record for NCT07173751 identifies the trial as a Phase 3, multisite study comparing pumitamig plus chemotherapy with placebo plus chemotherapy.
Who May Qualify for BNT327-05?
The official trial criteria include important medical details, so these points are only an initial guide. Potential participants generally must meet requirements such as the following:
- Be age 18 or older.
- Have locally recurrent, inoperable, or metastatic TNBC, or ER-low, HER2-negative breast cancer as defined by the protocol.
- Have a tumor that tested negative for PD-L1 and be considered ineligible for specified PD-1 or PD-L1 treatment combinations.
- Have received no prior systemic anticancer treatment for advanced disease.
- Have at least one measurable lesion under the study’s imaging criteria.
- Have an ECOG performance status of 0 or 1, a measure clinicians use to describe how well a person can carry out daily activities.
Reasons a Person May Not Qualify
Some exclusions may apply. For example, a person may not be eligible if they previously received systemic anticancer therapy for advanced disease or a PD-L1/VEGF bispecific antibody. Recent major surgery, certain infections or medications, a recent live vaccine, transplant history, pregnancy, breastfeeding, or other medical conditions may also affect eligibility.
Only the research team can make the final determination. They may review pathology reports, scan results, treatment records, laboratory results, medications, tissue samples, and reproductive health requirements before confirming whether participation is appropriate.
What Participation Can Involve
- Pre-screening and screening: This period may last up to one month and may include medical history review, physical assessments, blood tests, imaging, pathology review, and other protocol-required evaluations.
- Active treatment: Treatment may continue for up to 2 years if the participant is benefiting from and tolerating the assigned regimen.
- Follow-up: The research team monitors participants after treatment for at least 3 months, with periodic contact in accordance with the study procedures.
During active treatment, participants may have up to four study visits each month, and many visits can last three to five hours. The schedule, chemotherapy selection, travel distance, and needed testing should be discussed with the site before enrollment.
What Researchers Are Measuring
The study is designed to evaluate safety and effectiveness. Researchers may assess side effects, overall survival, progression-free survival, tumor response, and response duration. They will compare results between the pumitamig-plus-chemotherapy group and the placebo-plus-chemotherapy group.
These measures describe results across participant groups. They cannot predict exactly how any one person will respond. The randomized comparison helps researchers determine whether observed differences are attributable to the investigational treatment rather than chance alone.
Potential Benefits, Risks, and Practical Considerations
Possible Benefits
- Access to an investigational treatment that is not available through standard prescribing.
- Monitoring by a clinical research team.
- An opportunity to contribute to research for people with PD-L1-negative TNBC.
- No charge for the trial medicine or study-specific tests and procedures, subject to the protocol and local requirements.
Potential Risks and Limits
- Pumitamig may not work, and side effects can occur from investigational treatment, chemotherapy, study procedures, or the underlying cancer.
- Some participants will receive placebo plus chemotherapy rather than pumitamig plus chemotherapy.
- Routine care that is not study-specific may be handled through insurance or local billing policies.
- Frequent visits, travel, time away from work, and caregiver arrangements can be significant burdens.
How to Request Screening Information
- Ask the treating oncologist whether the disease setting and prior treatment history appear consistent with the trial.
- Confirm PD-L1 testing and gather pathology reports, imaging reports, medication lists, and treatment summaries.
- Contact the BNT327-05 research team through the official trial page to ask about pre-screening and local site availability.
- Ask which visits and tests are required, whether travel support is available, and which routine-care costs could remain the patient’s responsibility.
- Review alternatives, potential risks, and the possibility of placebo assignment with both the research team and the treating oncologist.
Recruiting Locations and Next Steps
BioNTech lists recruiting sites in the United States and other regions. Listed U.S. examples include sites in Springdale, Arkansas; La Jolla, Los Alamitos, Los Angeles, Palo Alto, and Sacramento, California. A trial can be recruiting overall even if an individual location has paused enrollment or reached capacity, so patients should verify the status of the specific site they plan to use.
Frequently Asked Questions
Is BNT327-05 an approved treatment?
No. Pumitamig is an investigational medicine in this study and is not approved for routine treatment of TNBC.
Will every participant receive pumitamig?
No. Participants are assigned by chance to receive either pumitamig plus chemotherapy or placebo plus chemotherapy.
Can men participate?
Yes. The trial is open to eligible adults of all sexes, subject to the complete protocol requirements.
Can a participant leave the trial?
Yes. Participants may withdraw at any time. They should speak with the research team and treating oncologist so that follow-up care can be planned safely.
Summary
BioNTech BNT327-05 is a recruiting Phase 3 trial evaluating pumitamig plus chemotherapy for selected adults with locally recurrent, inoperable, or metastatic TNBC, including people with PD-L1-negative disease who meet the protocol’s other requirements. The most reliable next step is to review the patient’s records with an oncology team and contact a recruiting study site for individualized eligibility screening.
